Difficulty: Medium
Average Score: 82%
Practice
Mr. Quince is a 68-year-old patient who describes several months of urinary frequency and a sensation of incomplete emptying with no associated dysuria, hematuria, or fever. Physical examination reveals a slightly enlarged but nontender prostate, a postvoid residual urine volume of 20 mL, and a urinalysis with 15 white blood cells (WBCs) and 5 red blood cells (RBCs). Urine culture reveals 30,000 colony-forming units of Escherichia coli. You see a report from last year that shows urinalysis with 10 WBCs and 4 RBCs that was obtained as part of a routine evaluation. What is the most appropriate next step in the management of Mr. QuinceÔÇÖs symptoms?
Correct answer
D
Rationale
The most appropriate next step in the management of Mr. Quince's symptoms is to start a 4-week course of ciprofloxacin (option D). This choice is based on the presence of urinary frequency, incomplete emptying, elevated WBCs in the urine, and the positive urine culture for Escherichia coli. These findings suggest a urinary tract infection (UTI), which is commonly caused by E. coli. Ciprofloxacin is a fluoroquinolone antibiotic effective against a broad spectrum of bacteria, including E. coli.
Starting an alpha-blocker (option A) would be more appropriate for managing symptoms of benign prostatic hyperplasia (BPH) such as urinary hesitancy or weak stream, not for treating a UTI. Similarly, initiating a 5-alpha-reductase inhibitor (option B) targets BPH, not an infection. Combination therapy with an alpha-blocker and a 5-alpha-reductase inhibitor (option C) is indicated for symptomatic BPH without evidence of infection, which is not the case here.
In an educational context, understanding the appropriate pharmacological interventions based on patient presentation, diagnostic findings, and underlying conditions is crucial in providing effective patient care. Differentiating between UTI symptoms and BPH symptoms and knowing the appropriate treatment modalities for each condition is essential for pharmacology students and healthcare professionals working in clinical settings.
Starting an alpha-blocker (option A) would be more appropriate for managing symptoms of benign prostatic hyperplasia (BPH) such as urinary hesitancy or weak stream, not for treating a UTI. Similarly, initiating a 5-alpha-reductase inhibitor (option B) targets BPH, not an infection. Combination therapy with an alpha-blocker and a 5-alpha-reductase inhibitor (option C) is indicated for symptomatic BPH without evidence of infection, which is not the case here.
In an educational context, understanding the appropriate pharmacological interventions based on patient presentation, diagnostic findings, and underlying conditions is crucial in providing effective patient care. Differentiating between UTI symptoms and BPH symptoms and knowing the appropriate treatment modalities for each condition is essential for pharmacology students and healthcare professionals working in clinical settings.